

RESEARCH HIGHLIGHTS

HIGHLIGHT ADVISORS

CEZMI AKDIS

SWISS INSTITUTE OF ALLERGY
AND ASTHMA RESEARCH,
SWITZERLAND

BRUCE BEUTLER

SCRIPPS RESEARCH INSTITUTE,
USA

PETER CRESSWELL

YALE UNIVERSITY, USA

JAMES DI SANTO

PASTEUR INSTITUTE, FRANCE

GARY KORETZKY

UNIVERSITY OF
PENNSYLVANIA, USA

CHARLES MACKAY

GARVAN INSTITUTE OF
MEDICAL RESEARCH,
AUSTRALIA

CORNELIS J. M. MELIEF

LEIDEN UNIVERSITY MEDICAL
CENTRE, THE NETHERLANDS

MICHEL NUSSENZWEIG

THE ROCKEFELLER UNIVERSITY,
USA

ALAN SHER

NATIONAL INSTITUTE OF
ALLERGY AND INFECTIOUS
DISEASE, USA

ANDREAS STRASSER

THE WALTER AND ELIZA HALL
INSTITUTE, AUSTRALIA

MEGAN SYKES

HARVARD MEDICAL SCHOOL,
USA

ERIC VIVIER

CENTRE D'IMMUNOLOGIE DE
MARSEILLE-LUMINY, FRANCE

MATTHIAS VON HERRATH

LA JOLLA INSTITUTE FOR
ALLERGY AND IMMUNOLOGY,
USA

NATURAL KILLER T CELLS

New lipid ligand nourishes NKT-cell responses

Most natural killer T (NKT) cells express a semi-invariant T-cell receptor (TCR) α -chain (V α 14–J α 18 in mice and the homologous V α 24–J α 18 in humans). These NKT cells recognize endogenous lipid antigens presented by the MHC-class-I-like molecule CD1d; however, the identity of the natural CD1d-bound ligands has not been established. But now, a paper published in *Science* shows that a lysosomal glycosphingolipid, isoglobotrihexosylceramide (iGb3), stimulates both human V α 24⁺ and mouse V α 14⁺ NKT cells.

Previous studies have shown that presentation of natural CD1d-bound ligands requires lysosomal trafficking of CD1d molecules and several lysosomal proteins, including proteases and lipid-transfer proteins, leading to the hypothesis that the endogenous ligands might be lysosomal glycosphingolipids. So, Zhou *et al.* analysed mice deficient in the B subunit of the lysosomal-glycosphingolipid-degrading enzyme β -hexosaminidase (HEXB) and found that the number of V α 14⁺ NKT cells was decreased by 95%. In addition, thymocytes that were isolated from HEXB-deficient mice could not stimulate interleukin-2 (IL-2) production by an autoreactive CD1d-restricted V α 14⁺ NKT-cell hybridoma, indicating that HEXB-deficient cells have a specific defect in generating lysosomal V α 14⁺ NKT-cell ligands.

HEXB-dependent enzymes remove the β -linked *N*-acetylgalactosamine (GalNAc) residues from several

distinct types of glycosphingolipid, such as isogloboglycosphingolipids. However, V α 24⁺ NKT cells present in freshly isolated peripheral-blood mononuclear cells (PBMCs) clonally expanded only in the presence of one of these glycosphingolipid types, iGb3. CD1d presentation of iGb3 also stimulated interferon- γ and IL-4 production by V α 24⁺ NKT cells and IL-2 production by the V α 14⁺ NKT-cell hybridoma. Furthermore, although HEXB-deficient bone-marrow-derived dendritic cells (BMDCs) presented iGb3 to the V α 14⁺ NKT-cell hybridoma as efficiently as wild-type BMDCs, they could not present the iGb3 precursor iGb4, indicating that iGb4 processing by HEXB-dependent enzymes is required for iGb3 recognition by the V α 14⁺ NKT cells.

Further evidence that iGb3 is a ligand for V α 14⁺ and V α 24⁺ NKT cells was provided by the observation that isolectin B4 (IB4) — a lectin isolated from *Griffonia simplicifolia* that binds the terminal Gal α 1,3-Gal of iGb3 — impaired iGb3 stimulation of V α 24⁺ NKT cells but not stimulation of V α 14⁺ NKT cells by an unrelated ligand, α -galactosylceramide. IB4 also inhibited V α 24⁺ NKT-cell recognition of natural CD1d ligands presented by PBMC-derived DCs.

This study defines iGb3 as an agonist ligand for V α 14⁺ and V α 24⁺ NKT cells, and the authors suggest that this might be the principal endogenous ligand for these cells that is expressed in non-diseased



peripheral tissues, as well as the ligand responsible for V α 14⁺ NKT-cell development. However, isogloboglycosphingolipids have not yet been biochemically identified in humans or mice, so further studies are required to confirm that iGb3 is indeed the principal self-antigen of V α 14⁺ and V α 24⁺ NKT cells.

Karen Honey

References and links

ORIGINAL RESEARCH PAPER Zhou, D. *et al.* Lysosomal glycosphingolipid recognition by NKT cells. *Science* **306**, 1786–1789 (2004).